Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Am J Clin Dermatol ; 20(2): 195-200, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-30390206

RESUMO

Alopecia encompasses a broad range of hair loss disorders, generally categorized into scarring and non-scarring forms. Depending on the specific pathogenesis of hair loss and geographic location, a number of psychiatric and medical comorbidities, including but not limited to thyroid disease, lupus erythematosus, diabetes mellitus, atopic dermatitis, sinusitis, coronary artery disease, anxiety, depression, and suicidality, have been identified in association with alopecia. In addition to the numerous associated comorbid conditions, patients with alopecia report decreased quality-of-life measures across symptomatic, functional, and global domains. While alopecia can affect patients of all ages, genders, and ethnicities, hair loss may more significantly impact women as hair represents an essential element of femininity, fertility, and female attractiveness in society. Individuals of lower socioeconomic status may also face health disparities in the context of alopecia as a majority of hair loss treatments are considered cosmetic in nature and accordingly are not covered by third-party insurance providers. Although traditionally thought of as a merely aesthetic concern, alopecia encompasses a significant burden of disease with well-defined comorbid associations and genuine psychosocial implications, and thus should be assessed and managed within a proper medical paradigm.


Assuntos
Alopecia/patologia , Disparidades nos Níveis de Saúde , Qualidade de Vida , Alopecia/psicologia , Alopecia/terapia , Cicatriz/etiologia , Comorbidade , Feminino , Humanos , Masculino , Fatores Socioeconômicos
2.
JAMA Dermatol ; 154(6): 670-675, 2018 06 01.
Artigo em Inglês | MEDLINE | ID: mdl-29641806

RESUMO

Importance: Endocrine therapy-induced alopecia (EIA) has been anecdotally reported but not systematically described. Objective: To characterize EIA in patients with breast cancer. Design, Setting, and Participants: Retrospective cohort study of 112 patients with breast cancer, diagnosed with EIA from January 1, 2009, to December 31, 2016, the patients were examined at the dermatology service in a large tertiary care hospital and comprehensive cancer center. Main Outcomes and Measures: The clinical features, alopecia-related quality of life (QoL), and response to minoxidil of EIA in patients with breast cancer were assessed. Data from the Hairdex Questionnaire was used to assess the impact of the alopecia on patients QoL. Higher score indicates lower QoL (0-100 score). Efficacy of minoxidil was measured at 3 or 6 months by a single-blinded investigator through standardized clinical photographs of the scalp. Results: A total of 112 female patients with breast cancer were included (median [range] age, 60 [34-90] years). A total of 104 patients (93%) had standardized clinical photographs; of these, 59 patients (53%) had trichoscopy images available at baseline, and 46 patients (41%) were assessed for response to minoxidil. Alopecia was attributed to aromatase inhibitors in 75 patients (67%) and tamoxifen in 37 (33%). Severity was grade 1 in 96 of 104 patients (92%), and the pattern was similar to androgenetic alopecia. The predominant trichoscopic feature at baseline was the presence of vellus hairs and intermediate- and thick-diameter terminal hair shafts. A negative impact on QoL was reported, with a higher effect in the emotion domain according to the Hairdex score (mean [SD], 41.8 [21.3]; P < .001). After treatment with topical minoxidil, moderate or significant improvement in alopecia was observed in 37 of 46 patients (80%). Conclusions and Relevance: Endocrine therapies are associated with a pattern alopecia similar to androgenetic-type, consistent with the mechanism of action of causal agents. A significant negative impact on QoL was reported by patients, despite mostly mild alopecia severity.


Assuntos
Alopecia/tratamento farmacológico , Antineoplásicos Hormonais/efeitos adversos , Neoplasias da Mama/tratamento farmacológico , Minoxidil/uso terapêutico , Qualidade de Vida , Vasodilatadores/uso terapêutico , Adulto , Idoso , Idoso de 80 Anos ou mais , Alopecia/induzido quimicamente , Alopecia/psicologia , Inibidores da Aromatase/efeitos adversos , Dermoscopia , Emoções , Feminino , Humanos , Pessoa de Meia-Idade , Estudos Retrospectivos , Método Simples-Cego , Tamoxifeno/efeitos adversos
3.
J Drugs Dermatol ; 16(5): 496-500, 2017 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-28628687

RESUMO

Biotin, also known as Vitamin B7 or vitamin H, is a water-soluble B vitamin that acts as an essential cofactor for several carboxylases involved in the cellular metabolism of fatty acids, amino acids, and gluconeogenesis. Although there exists an incredible amount of social media hype and market advertising touting its efficacy for the improvement of hair quantity and quality, biotin's efficacy for hair remains largely unsubstantiated in scientific literature. We reviewed all pertinent scientific literature regarding the efficacy of biotin supplementation for hair growth and quality improvement, and we also investigated its popularity in society defined as a function of market analytics. To date, there have been no clinical trials conducted to investigate the efficacy of biotin supplementation for the treatment of alopecia of any kind, nor has there been any randomized controlled trial to study its effect on hair quality and quantity in human subjects. Because of the lack of clinical evidence, its use to improve hair quantity or quality is not routinely recommended. However, societal infatuation with biotin supplementation is not only propagated by its glamorization in popular media, its popularity is vastly disproportionate to the insufficient clinical evidence supporting it's efficacy in hair improvement. In other words, biotin supplements are quite "in vogue", without there being any real reason to be so.

J Drugs Dermatol. 2017;16(5):496-500.

.


Assuntos
Alopecia/tratamento farmacológico , Biotina/administração & dosagem , Suplementos Nutricionais , Mídias Sociais/tendências , Percepção Social , Alopecia/diagnóstico , Alopecia/psicologia , Humanos , Resultado do Tratamento
4.
Therapie ; 71(3): 263-73, 2016 Jun.
Artigo em Francês | MEDLINE | ID: mdl-27235649

RESUMO

INTRODUCTION: In Europe, breast cancer is the most common cancer among women. His treatment (TTT) can have a significant impact on daily life. AIMS: Explore the experienced short-term side effects (SE) of chemotherapy and hormonal therapy by women themselves, the information delivered and the place of the general practitioner (GP). METHOD: Qualitative study by individual interview, conducted from January to May 2015, with 14 women followed for no metastatic breast cancer after chemotherapy and possible initiation of hormone therapy, at the Cancer Institute of the Loire (France). RESULTS: The SE of chemotherapy, except vomiting, have appeared very trying (fatigue, pains oral and cutaneous involvement), punctuated and accentuated by the cures. They were resounding on daily life, requiring family or professional assistance. Falling dander, considered stigmatizing, violated the person and femininity. The women have estimated to be well informed. They had appreciated the initial response of the pivot nurse. The least expected SE of hormone therapy, hot flashes and articular pains might limit activities. To counteract these side effects, mostly accepted to prevent recidivism, a remedy for complementary therapies was frequent. The GP was solicited for some SE, sometimes for complementary medicine (CM). CONCLUSION: Over the cures, women suggested support meetings, a more sustainable action of the pivot nurse, a better attention to their complaints and a more personalized information. The development of TTT less EI provider was desired. The effect of CM on SE should be explored.


Assuntos
Antineoplásicos/efeitos adversos , Neoplasias da Mama/tratamento farmacológico , Adulto , Idoso , Alopecia/induzido quimicamente , Alopecia/psicologia , Antineoplásicos Hormonais/efeitos adversos , Neoplasias da Mama/psicologia , Terapias Complementares/estatística & dados numéricos , Toxidermias/etiologia , Toxidermias/psicologia , Fadiga/induzido quimicamente , Fadiga/psicologia , Feminino , Febre/induzido quimicamente , Humanos , Pessoa de Meia-Idade , Doenças da Boca/induzido quimicamente , Dor/induzido quimicamente , Educação de Pacientes como Assunto , Pesquisa Qualitativa , Qualidade de Vida
5.
Med. cután. ibero-lat.-am ; 40(4): 103-108, jul.-ago. 2012. ilus
Artigo em Espanhol | IBECS | ID: ibc-103021

RESUMO

Fundamento: Es sabido que la alopecia femenina provoca una intensa repercusión en el psiquismo. Sin embargo, no existen estudios que calibren los cambios que puedan producirse en el mismo, cuando el aspecto de la paciente mejora gracias a la implantación de un Sistema de Integración Capilar. Un Sistema de Integración Capilar (SIC) es una prótesis parcial de cabello, de carácter semipermanente, personalizada, hecha a mano con pelos naturales de iguales características de color, grosor y textura al cabello del paciente, que se ajusta a la porción del cuero cabelludo carente de pelo y que se integra, sin intervención quirúrgica, cabello a cabello ocultando las zonas afectadas y creando una apariencia homogénea. El objetivo de este trabajo es conocer en qué medida la implantación del SIC mejora el estado psicológico de las pacientes que sufren alopecia de diferentes tipos. Material y método: Se estudió en 24 mujeres con alopecia moderada-grave de diferentes tipos que acudieron de forma sucesiva al Instituto Médico Dermatológico (IMD) de Madrid (España) entre febrero y julio de 2011 para ser tratadas con SIC. Se completó el cuestionario Hospital Anxiety and Depression Scale (HADS) antes y 3 meses después de la implantación del SIC. Se comparó la evolución en el tiempo de los cuadros de ansiedad y depresión a través del test de McNemar como herramienta estadística. Resultados: Ansiedad: al inicio del estudio el 83,33% de las pacientes mostraban diferentes niveles de ansiedad. A los 3 meses de la (AU)


Rationale: It is well know that female alopecia has a severe psychological impact. However, there are no studies assessing the psychological changes that may occur when the patient’s image improves due to the implementation of a Hair Integration System (HIS). A HIS is a partial, personalized, semipermanent hair prosthesis made of natural hair with the same characteristics of color, thickness, and texture than the patient’s hair and that is adjusted to the portion of the scalp lacking the hair and that is integrated hair by hair without any surgical intervention, covering the areas affected and yielding a homogenous appearance. The aim of this work was to know to what extent the implantation of HIS improves the psychological status of patients suffering from different types of alopecia. Material and methods: We studied 24 women with severe to moderate alopecia of different types consecutively consulting to the Instituto Médico Dermatológico (IMD) of Madrid (Spain) between February and July of 2011 to be treated by HIS. The patients completed the Hospital Anxiety and Depression Scale (HADS) before and 3 months after the implantation of HIS. The time course of anxiety and depression disorders was compared by using the McNemar test. Results: Anxiety: at the study beginning, 83.33% of the patients showed different anxiety levels. Three months after the implantation of HIS, 74.99%of the patients showed a statistically significant improvement (p value < 0.01) in the anxiety status. Depression: at the study beginning, 66.67% of the patients showed depression signs. Three months after, the signs of depression were no longer existent in 100% of the patients. Conclusions: this study confirms that alopecia disorders have a negative psychological impact (anxiety, depression) in women. HIS is an efficacious tool for the cosmetic treatment of alopecia, with almost immediate positive psychological effects (AU)


Assuntos
Humanos , Feminino , Alopecia/psicologia , Cabelo/transplante , Psicometria/instrumentação , Ansiedade/epidemiologia , Depressão/epidemiologia , Mulheres/psicologia
7.
Gan To Kagaku Ryoho ; 34(3): 435-8, 2007 Mar.
Artigo em Japonês | MEDLINE | ID: mdl-17353638

RESUMO

The patient was a 36-year-old woman, who found a mass in her right breast around April 2002, visited a physician in June, and was referred to our department because of suspected right breast cancer. It was confirmed that the cancer had metastasized to the right axillary lymph nodes and the skin of the right breast. After undergoing an operation on July 11 (Bt+Ax), the patient was placed on tamoxifen (TAM). Then, the course was followed while the patient was treated with CEF and 5'-DFUR. In April 2004, she had a recurrence manifesting itself as bone metastasis, partly because of poor compliance with the hospital-visit and dosing schedules. After chemotherapy with paclitaxel, etc., combination therapy with docetaxel (DOC), capecitabine, and high-dose (120 mg/day) toremifene (TOR) was started on October 15, 2004. Subsequently, because the patient firmly resisted hair loss, chemotherapy was continued with a double-drug regimen with capecitabine and high-dose TOR. Treatment was temporarily discontinued because the patient developed hand-foot syndrome, which was probably attributable to capecitabine, but the symptoms improved after administration of vitamin B(6). Thereafter,the patient complied well with the dosing schedule, and no new metastatic focus has been detected by any examination as of October 2005. These findings suggest that the double-drug regimen with capecitabine and high-dose TOR is an effective treatment for patients who can not be treated with anthracyclines or taxanes.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Linfonodos/patologia , Recidiva Local de Neoplasia/tratamento farmacológico , Adulto , Alopecia/psicologia , Neoplasias Ósseas/secundário , Neoplasias da Mama/patologia , Neoplasias da Mama/cirurgia , Capecitabina , Terapia Combinada , Desoxicitidina/administração & dosagem , Desoxicitidina/análogos & derivados , Relação Dose-Resposta a Droga , Esquema de Medicação , Feminino , Fluoruracila/administração & dosagem , Fluoruracila/análogos & derivados , Humanos , Metástase Linfática , Mastectomia Segmentar , Qualidade de Vida , Toremifeno/administração & dosagem
8.
Cancer Pract ; 9(6): 283-9, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11879330

RESUMO

PURPOSE: This article reviews the relevant literature on treatment-induced alopecia in women with cancer and describes the development of a computer-assisted intervention to reduce distress associated with this side effect. DESCRIPTION OF PROGRAM: Alopecia has been cited as the most disturbing anticipated side effect by up to 58% of women preparing for chemotherapy, with 8% being at risk for avoiding treatment. Women with cancer who experience alopecia as a side effect, compared with women with cancer and no alopecia, report lower self-esteem, poorer body image, and lower quality of life. Although physicians' recommendations are the most influential factor on cancer treatment choice, body image and effects on sexuality are the next most influential factors. A study of a computer-imaging intervention, based on concepts related to guided imagery and anticipatory grief, has been launched in an effort to aid women in coping with anticipated treatment-related alopecia. RESULTS: While we are still waiting for final data collection and analysis from the computer intervention study, the feedback thus far has been positive. CLINICAL IMPLICATIONS: The intervention described here may prove to be effective in desensitizing women with cancer to hair loss and facilitating an adjustment to self-acceptance. As such, a higher quality of life during the difficult time of coping may be maintained. The development of a computer-imaging intervention offers an opportunity to integrate a standard psychosocial intervention, personalized for each patient, into the routine patient care in the oncology setting.


Assuntos
Alopecia/psicologia , Antineoplásicos/efeitos adversos , Neoplasias/tratamento farmacológico , Neoplasias/psicologia , Mulheres/psicologia , Adaptação Psicológica , Alopecia/induzido quimicamente , Feminino , Humanos , Qualidade de Vida
10.
Psychother Psychosom ; 56(4): 235-41, 1991.
Artigo em Inglês | MEDLINE | ID: mdl-1801046

RESUMO

Mental stress and immunological abnormality have recently been listed as causes of alopecia universalis. This disease is difficult to treat with only ordinary pharmacotherapy. Thus, from the standpoint of psychoneuroimmunology, stress was relieved by relaxation and image therapy, and administration of small doses of a strong immunosuppressant was effective, leading to clinically favorable results. In addition, changes were recognized in the subpopulation of peripheral lymphocytes and in beta-endorphin before and after relaxation and image therapy. The treatment of alopecia universalis favorably changed the subpopulations of T cells. A patient suffering from alopecia is always under stress. Alleviating this stress facilitates recovery of immunological competence. Our method was effective in 5 of 6 cases with refractory alopecia universalis.


Assuntos
Alopecia/terapia , Imunossupressores/uso terapêutico , Psicoterapia , Estresse Psicológico/psicologia , Adolescente , Adulto , Alopecia/psicologia , Treinamento Autógeno , Criança , Feminino , Humanos , Imaginação , Masculino , Psiconeuroimunologia , Linfócitos T , beta-Endorfina/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA